

Reviewer Relationships With Industry and Other Entities (Comprehensive) — 2019 Expert Consensus Decision Pathway Methodology

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
C. Michael Valentine	Official Reviewer—ACC President	Stroobants Cardiovascular Center of Centra Health—Senior Cardiologist; American College of Cardiology, President	None	None	None	None	None	None
Barbara S. Wiggins	Official Reviewer—Task Force on Expert Consensus Decision Pathways	Medical University of South Carolina—Clinical Pharmacy Specialist Cardiology, Department of Pharmacy Services	None	None	None	None	None	None
Karen P. Alexander	Content Reviewer—Expert Consensus Decision Pathway Writing Committees	Duke University Medical Center—Professor of Medicine/Cardiology	None	None	None	<ul style="list-style-type: none"> • GlaxoSmithKline • NIH 	None	None
Biykem Bozkurt	Content Reviewer—Expert Consensus Decision Pathway Writing Committees	DeBakey VA Medical Center—The Mary and Gordon Cain and W.A. “Tex” and Deborah Moncrief, Jr., Chair; Professor of Medicine, Medical Care Line Executive; Baylor College of Medicine—Director, Winters Center for Heart Failure Research; Associate Director, Cardiovascular Research Institute; Vice-Chair of Medicine	<ul style="list-style-type: none"> • Bayer HealthCare Pharmaceuticals • Lantheus Medical Imaging 	None	None	<ul style="list-style-type: none"> • LivaNova (DSMB) 	<ul style="list-style-type: none"> • Novartis* 	None
John U. Doherty	Content Reviewer—Expert Consensus Decision Pathway Writing Committees	Jefferson Heart Institute at Sidney Kimmel Medical College Director of Clinical Services	None	None	None	None	None	<ul style="list-style-type: none"> • Defendant, Failure to bridge after interruption of warfarin,

								2018† • Third party, Product liability for anticoagulant Xaralto, 2018†
Ty J. Gluckman	Content Reviewer—Roundtable Planning Committee	Providence Heart and Vascular Institute—Medical Director	• Boehringer Ingelheim	None	None	None	None	None
Julia H. Indik	Content Reviewer—Heart Rhythm Society, Chair of Clinical Documents Committee	University of Arizona Medical Center—Associate Professor of Medicine	None	None	None	• NIH	None	None
Glenn N. Levine	Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines, Chair	Baylor College of Medicine—Master Clinician and Professor of Medicine; Michael E. DeBakey Medical Center—Director, Cardiac Care Unit	None	None	None	None	None	• Defendant, Out of hospital cardiopulmonary arrest, 2017† • Defendant, Out of hospital death, 2018†
Melissa Magwire	Content Reviewer—Expert Consensus Decision Pathway Writing Committees	Shawnee Mission Endocrinology & Diabetes—Clinical Supervisor	None	• Janssen Pharmaceuticals • Novo Nordisk • Sanofi-Aventis	None	None	None	None
Catherine M. Otto	Content Reviewer—Expert Consensus Decision Pathway Writing Committees	J. Ward Kennedy-Hamilton Endowed Chair in Cardiology—Editor-in-Chief, Heart; University of Washington—Professor of Medicine	None	None	None	None	None	None
Sarah A. Spinler	Content Reviewer—Roundtable Planning	Philadelphia College of Pharmacy University of the	• Portola Pharmaceuticals	• Bristol-Myers Squibb	None	None	None	None

	Committee	Sciences in Philadelphia— Professor of Clinical Pharmacy	• Regeneron					
Salim S. Virani	Content Reviewer— Roundtable Planning Committee	Baylor College of Medicine—Associate Professor	None	None	None	<ul style="list-style-type: none"> • ADA† • AHA† • Baylor College of Medicine† • Department of Veterans Affairs 	<ul style="list-style-type: none"> • ACC† • NLA 	None
Mary Norine Walsh	Content Reviewer— Expert Consensus Decision Pathway Writing Committees	St. Vincent Heart Center— Medical Director, Heart Failure and Cardiac Transplantation; American College of Cardiology— Immediate Past President	None	None	None	None	<ul style="list-style-type: none"> • PCORI* • Thoratec* 	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

* Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

†Significant relationship.

ACC=American College of Cardiology; ADA=American Diabetes Association; AHA=American Heart Association; DSMB=Data Safety Monitoring Board; NIH=National Institutes of Health; NLA=National Lipid Association; PCORI=Patient-Centered Outcomes Research Institute.